

RECEIVED
JAN 02 2003
TECH CENTER 1600/2900

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/067,555	FILE NOCKET NO.: B00801.70233.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: October 25, 2001	CONFIRMATION NO.: 5204
	APPLICANT: Colgan et al.	
	GROUP ART UNIT: 1614	EXAMINER: unknown
Sheet 1 of 1		

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
my	B1	WO	96/39426	A1	PCT	12-12-1996	
	B2	WO	98/14615	A1	PCT	04-09-1998	
	B3	WO	99/09046	A1	PCT	02-25-1999	
	B4	WO	00/69908	A1	PCT	11-23-2000	
	B5	WO	02/02609	A1	PCT	01-10-2002	


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
my	C1	CANIGGIA et al., "Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ ₃ ," <i>J. of Clinical Investigation</i> , Vol.105, No. 5, March 2000, pp.577-587.		
	C2	COMERFORD et al., "Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance (MDR1) Gene" <i>Cancer Research</i> , 62, pp.3387-3394, June 15, 2002.		
	C3	SEMENZA et al., "Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression." <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 35(2); 71-103 (2000).		
	C4	SEMENZA et al., "Hypoxia-inducible factor 1: master regulator of O ₂ homeostasis." <i>Current Opinion in Genetics & Development</i> , vol. 8, no. 5, October 1998, pp.588-594.		
	C5	WALLACE et al. "Induction of multidrug resistance (mdr-1) gene by hypoxia," <i>Molecular Biology of the Cell</i> , Vol. 11, no. Supplement, December 2000, p. 435a. (abstract)		
	C6	Communication Relating to the Results of the Partial International Search, PCT/US01/49856, November 18, 2002		

EXAMINER <i>misob y</i>	DATE CONSIDERED <i>2-11-05</i>
----------------------------	-----------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).



FEB 06 2003

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 1 of 1

APPLICATION NO.: 007,255

ATTY. DOCKET NO.: B00801.70233.US

FILING DATE: October 25, 2001

CONFIRMATION NO.: 5204

APPLICANT: Colgan et al.

GROUP ART UNIT: 1614

EXAMINER: unknown

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
my	A1	5,882,914	A	Semenza	03-16-1999
	A2	6,001,991	A	Dean, et al.	12-14-1999
	A3	6,020,462	A	Semenza	02-01-2000


FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
my	C7	BROWN, JM "Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies." <i>Molecular Medicine Today</i> . 6:157-162 (April 2000).		
	C8	FARDEL, O., et al. "The P-glycoprotein multidrug transporter." <i>Gen Pharmacol.</i> 27(8):1283-91 (1996)		
	C9	JIN, S., et al. "Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y." <i>Molecular and Cellular Biology</i> 18:4377-4384 (1998).		
	C10	KAYE, SB. "Multidrug resistance: clinical relevance in solid tumors and strategies for circumvention." <i>Curr Opin Oncol.</i> 10(suppl. 1):S15-S19. (1998)		
	C11	LIANG, BC., "Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines." <i>J Neuro-Oncology</i> . 29:149-155 (1996).		
	C12	RYAN, HE., et al. "HIF-1 α is required for solid tumor formation and embryonic vascularization." <i>EMBO Journal</i> . 17(11):3005-3015 (1998).		
	C13	SEMENTA, GL., et al. "Regulation of mammalian O ₂ homeostasis by hypoxia-inducible factor 1." <i>Annu. Rev. Cell Dev Biol.</i> 15:551-78 (1999)		
	C14	STRAUSS, BE et al., "The region 3' to the major transcriptional start site of the mdr1 downstream promoter mediates activation by a subset of mutant P53 proteins." <i>Biochem Biophys Res Commun.</i> 217(1):333-340 (1995).		
	C15	SUTHERLAND, RM "Tumor hypoxia and gene expression - implications of malignant progression and therapy." <i>Acta Oncol.</i> 37(6):567-74. (1998).		
	C16	UEDA, K "Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine." <i>Proc. Natl. Acad. Sci. USA</i> 84:3004-3008 (1987).		
	C17	UEDA, K., et al. "Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene." <i>J. Biol. Chem.</i> 262(36):17432-17436 (1987).		
	C18	UEDA, K., et al. "The human multidrug resistance (mdr1) gene." <i>J. Biol. Chem.</i> 262(2):505-508 (1987)		
	C19	UEDA, K., et al. "The mdr1 gene, responsible for multidrug-resistance codes for p-glycoprotein." <i>Biochem Biophys Res Commun.</i> 141(3):956-962. (1986).		
EXAMINER		DATE CONSIDERED		
Misord		2-11-05		

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 10/007,255		ATTY DOCKET NO.: B0080170233 US	
	FILING DATE: October 25, 2001		CONFIRMATION NO.: 5204	
	APPLICANT: Colgan et al.			
	GROUP ART UNIT: 1614		EXAMINER: unknown	
Sheet 1 of 1				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of Issue of Cited Document
		Number	Kind Code		
					MAR 24 2003
					TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
my	B6	WO	98/20038		The Univ. of Texas, Board of Res.	05-14-1998	
↓	B7	WO	00/36148		Isis Pharmaceuticals, Inc.	06-22-2000	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
my	C7	KRETZ-REMY et al., "SUMO/sentrin: protein modifiers regulating important cellular functions," <i>Biochem Cell Biol.</i> , 77: 299-309 (1999).		
↓	C8	MAO et al., "SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage," <i>PNAS</i> , 97, No. 8: 4046-4051 (2000).		
↓	C9	International Search Report for PCT/US01/49856; Date of Search: February 6, 2003 (Mailed February 17, 2003).		

EXAMINER <i>Misosh 7</i>	DATE CONSIDERED <i>2-11-05</i>
--------------------------	--------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications)

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]